Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimal Combination Therapy After Nevirapine Exposure

Next Previous
X
Search
Trial Profile

Optimal Combination Therapy After Nevirapine Exposure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nevirapine (Primary) ; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OCTANE; OCTANE-1

    • Most Recent Events

    • 07 Mar 2018 Results assessing association between virological failure of ART and HIV variant with dual-class resistance by using data from this study presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and HPTN 052 and ACTG A5175 trial, were presented at the 9th International AIDS Society Conference on HIV Science
    • 08 Mar 2012 Extension study results presented at the 19th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top